[go: up one dir, main page]

WO2008018118A1 - Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant - Google Patents

Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant Download PDF

Info

Publication number
WO2008018118A1
WO2008018118A1 PCT/JP2006/315612 JP2006315612W WO2008018118A1 WO 2008018118 A1 WO2008018118 A1 WO 2008018118A1 JP 2006315612 W JP2006315612 W JP 2006315612W WO 2008018118 A1 WO2008018118 A1 WO 2008018118A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
skin
antioxidant
negararidake
whitening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2006/315612
Other languages
English (en)
Japanese (ja)
Inventor
Rika Negishi
Masaki Arashima
Sayaka Aramaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noevir Co Ltd
Original Assignee
Noevir Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co Ltd filed Critical Noevir Co Ltd
Priority to JP2008528670A priority Critical patent/JP5014343B2/ja
Priority to PCT/JP2006/315612 priority patent/WO2008018118A1/fr
Publication of WO2008018118A1 publication Critical patent/WO2008018118A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9728—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • Nemagari-dake-containing composition moisturizer, cell activator, whitening agent and antioxidant
  • the present invention relates to a nematode-containing composition, a humectant, a cell activator, a whitening agent and an antioxidant.
  • Patent Document 1 bamboo sasa plants, health foods and oral anti-tumor agents (Patent Document 2), anti-tumor agent compositions (Patent Document 2), anti-allergies that contain the extract as an active ingredient Agents (Patent Document 3) and antibacterial agents (Patent Document 4) are known.
  • Negararidake Puloaceae, Sara kurilensis
  • the extract is formulated as a keratinase inhibitor into a topical skin preparation (Patent Document 5), and into a cosmetic for hair.
  • Patent Document 6 a cosmetic liquid containing tishima zasa distillate obtained by fractionating a squeezed juice obtained by squeezing raw leaves and stems of chishima zasa (also known as nematode mushroom) (Patent Document 7).
  • Patent Document 1 Japanese Patent Application Laid-Open No. 2004-337151
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2004-359698
  • Patent Document 3 Japanese Patent Laid-Open No. 9-278662
  • Patent Document 4 Japanese Patent Laid-Open No. 11-269020
  • Patent Document 5 Japanese Unexamined Patent Application Publication No. 2004-161621
  • Patent Document 6 Japanese Unexamined Patent Application Publication No. 2004-196731
  • Patent Document 7 Japanese Patent Application Laid-Open No. 2004-224750
  • the present invention is a composition derived from a natural product that can be widely applied in the field of external preparations for skin and foods and drinks, and can be applied to a humectant, a cell activator, a whitening agent, or an antioxidant.
  • the object is to provide a composition.
  • the present invention provides a nematode mushroom-containing composition having nematode mushroom as an active ingredient and having moisturizing, cell activation, whitening or antioxidant action.
  • Nemadaridake Pane Sasa, Scientific name: Sara kurilensis
  • it has excellent cell activation effect (anti-aging effect), collagen production promotion effect, antioxidant effect and melanin production inhibitory effect, and it is a moisturizer, cell activator, whitening agent or antioxidant.
  • the present inventors have found that it can be applied as an active ingredient and have completed the present invention.
  • Negararidake As an active ingredient in this way, a moisturizer, cell activator, whitening agent or antioxidant can be obtained.
  • a moisturizer for application to the skin a moisturizer for skin
  • a cell activator it can be used particularly effectively as a dermal fibroblast activator.
  • Negaridae functions as a tyrosinase activity inhibitor, and as a result, whitening effect is considered to be obtained.
  • Negaridae is also effective as a radical scavenger (radical scavenger), and it is thought that an antioxidant effect can be obtained by scavenging free radicals.
  • the present invention provides use (use method) of Negararidake as a moisturizer, cell activator, whitening agent or antioxidant.
  • Negararidake-containing composition that can be widely applied in the fields of external preparations for skin and foods and drinks, and can be applied as a moisturizer, cell activator, whitening agent or antioxidant.
  • This composition can be used as a moisturizer, cell activator, whitening agent or antioxidant having an excellent effect.
  • negararidake by adding negararidake to a composition such as an external preparation for skin and foods and drinks, it is possible to obtain an excellent effect in preventing and improving skin symptoms such as wrinkles, tarmi, skin firmness, spots, and scum.
  • Neakaridake (Sara kurilensis), which is a plant used as a raw material of the present invention, is a plant belonging to the genus Sasa of the family Gramineae. Nemagari-dake (Negakutake) is also known as Chishimazasa, Jitake, etc., and is grown in the Tohoku region and Hokkaido from the Sea of Japan in Honshu, Japan and north of Tottori Prefecture, and is available in these regions. .
  • Negararidake for extraction, it can be used after being pulverized as it is.
  • Nemagaritake may use any part of leaves, stems, roots, buds, flowers, etc., or a combination thereof, which may use the whole tissue for extraction. Since the above-described effects are more excellent, young shoots that preferably use shoots as nematode are more preferable.
  • the extraction it may be used as it is, but in consideration of the extraction efficiency, the amount of the extracted component, etc., the extraction can also be performed after processing such as shredding, drying, and pulverization.
  • an extraction method using immersion in an extraction solvent or using a supercritical fluid or a subcritical fluid can be applied.
  • the extraction force with stirring may be extracted after homogenizer or a mixer or the like is used to homogenize the raw material in the extraction solvent.
  • the extraction solvent is water; lower alcohols such as methanol, ethanol, propanol, isopropanol (referred to as alcohols having 6 or less carbon atoms; the same shall apply hereinafter); 1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin
  • Polyhydric alcohols such as: ethers such as ethyl ether and propyl ether; esters such as butyl acetate and ethyl acetate; ketones such as acetone and ethyl methyl ketone can be used, and one or two of them can be used. The above is selected and used.
  • the lower alcohols, polyhydric alcohols, ethers, esters and ketones correspond to polar organic solvents.
  • physiological saline physiological saline, phosphate buffer, phosphate buffered saline, or the like may also be used.
  • supercritical fluids and subcritical fluids such as ammonia may be used. That is, supercritical extraction and subcritical extraction may be performed using water, carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia, and the like.
  • the extraction temperature is suitably from about 0 ° C to 5 ° C to below the boiling point of the extraction solvent.
  • the extraction time varies depending on the type of extraction solvent and the extraction temperature, but is preferably about 1 hour to 14 days.
  • the critical temperature and critical pressure are determined according to the medium used. For example, when the medium is carbon dioxide, the critical temperature is 31 ° C, the critical pressure is 7.3 MPa, when the medium is methanol, the critical temperature is 239 ° C, the critical pressure is 8. lMPa, and when the water is water, the critical temperature is 374 ° C, Critical pressure 22. Can be set to IMPa.
  • Particularly preferred as the extraction of the oyster mushroom is extraction with a lower alcohol aqueous solution (for example, a methanol aqueous solution or an ethanol aqueous solution, particularly an ethanol aqueous solution) at a normal temperature and normal pressure, and a high temperature (for example, 50 to 200 ° C, preferably 50 ( ⁇ 150 ° C, in particular 120 ° C) extraction with water under caloric pressure.
  • a lower alcohol aqueous solution for example, a methanol aqueous solution or an ethanol aqueous solution, particularly an ethanol aqueous solution
  • a high temperature for example, 50 to 200 ° C, preferably 50 ( ⁇ 150 ° C, in particular 120 ° C
  • the extract of Nemagari-dake with the above solvent can be used as it is.
  • the concentrated, dried product can be used again by dissolving it in water or a polar solvent. Further, it may be used after performing purification treatment such as decolorization, deodorization, desalting, etc. and fractionation treatment by column chromatography etc. within the range not impairing these physiological functions.
  • the above-mentioned extract of Negaridae, its processed products and fractions can be lyophilized after each processing and fractionation, and dissolved in a solvent before use.
  • An extract of Negaridae has an excellent moisturizing action, cell activation action, whitening action, and antioxidant action, and the moisturizing agent, cell activator, whitening agent, antioxidant, external preparation for skin, and food and drink Goods Can be used as
  • moisturizers, cell activators, whitening agents, and antioxidants which are made from the extract of Negararidake, can be used for hair that is not only applied to the skin but also can be taken orally. It can also be applied to pharmaceuticals.
  • a moisturizing agent containing an extract of Nemadaritake mushroom as an active ingredient exhibits an excellent moisturizing action on the skin and hair, and particularly has a high moisturizing effect on the skin.
  • a cell activator comprising an extract of Nemadaritake as an active ingredient exhibits an excellent activation effect on various cells, but particularly exhibits an excellent effect on dermal fibroblasts.
  • a whitening agent containing an extract of Nemagari-dake is effective for improving pigmentation symptoms such as stains and freckles, and is particularly effective for suppressing melanin production based on inhibition of tyrosinase activity. To do.
  • An antioxidant comprising an extract of Negaridae as an active ingredient exerts an excellent effect on the ability to exert an excellent antioxidant action, particularly a free radical scavenging action (action as a radical scavenger).
  • Negararidake extract in addition, by incorporating Negararidake extract into an external preparation for skin, it exhibits an excellent effect in preventing and improving skin symptoms such as wrinkles, tarmi, skin firmness, spots, Tasumi, dryness, and fine wrinkles.
  • a skin external preparation can be obtained, and can also be used as a skin external preparation for improving anti-aging or a skin external preparation for whitening.
  • the extract of Negararidake can also be used in foods and beverages for the purpose of beauty, health maintenance or nutritional supplementation.
  • Negararidake extract to be added to a skin external preparation as a moisturizer, cell activator, whitening agent, or antioxidant should be adjusted according to the type of skin external preparation, purpose of use, etc. but it is, in terms of effect and stability, 0001-50. it is preferably 0 wt% 0.1 of the total amount, more preferably 0. 001-25. 0 wt 0/0.
  • the dosage form of the external preparation for skin (humectant, cell activator, whitening agent, anti-oxidant agent, etc.) containing the extract of Negararidake is arbitrary, for example, soluble wrinkles such as lotion, It can be provided as a dispersion system such as an emulsification system such as cream or emulsion, or a calamine lotion. Furthermore, it can also be provided in various dosage forms such as aerosols, ointments, powders, granules filled with propellants.
  • the extract of Negaridae is used as a moisturizer, cell activator, whitening agent, antioxidant, etc.
  • oil preparations and moisturizing agents are usually included in pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents as needed.
  • Agents, powders, pigments, emulsifiers, solubilizers, detergents, ultraviolet absorbers, thickeners, drugs, fragrances, scabs, antibacterial / antifungal agents, alcohols and the like can be appropriately blended.
  • other cell activators, whitening agents, and antioxidants can be used in combination as long as the effects of the present invention are not impaired.
  • a sample obtained according to the production method described in Production Example 1 was used.
  • the evaluation was performed according to the following procedure. Normal human dermal fibroblasts were seeded in 96-well microphone mouthplates at 2.0 ⁇ 10 4 per well.
  • As the seeding medium Dulbecco's modified Eagle medium (DMEM) supplemented with 1% by weight of urine fetal serum (FBS) was used. After culturing for 24 hours, the medium was replaced with a sample prepared at each concentration in DMEM medium supplemented with 1% by mass FBS, and further cultured for 48 hours.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the medium was replaced with a medium containing 400 ⁇ gZmL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and cultured for about 2 hours.
  • Formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol.
  • the absorbance at 550 nm was measured with a microplate reader, and at the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • the evaluation results are shown in Table 1 as relative values with the cell activation effect in DMEM medium (blank) with 1% by mass FBS added without sample as 100.
  • a sample obtained according to the production method described in Production Example 1 was used.
  • the evaluation was performed according to the following procedure. Normal human dermal fibroblasts were seeded in 96-well microphone mouthplates at 2.0 ⁇ 10 4 per well.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 0.5% by weight urchin fetal serum (FBS). After culturing for 24 hours, the medium was replaced with a sample prepared at various concentrations in DMEM medium supplemented with 1% by mass FBS, and further cultured for 24 hours.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urchin fetal serum
  • type I collagen secreted into the culture supernatant was measured using an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • type I collagen in the culture supernatant is reacted with a rabbit anti-human type I collagen polyclonal antibody (CHEMICON) and then labeled with a peroxidase-labeled anti-rabbit IgG polyclonal antibody (HISTOFINE; -Chilei) as a secondary antibody. did.
  • the labeled peroxidase was reacted with 2,2,1-azinobis (3-ethylbenzothiazoline 6-sulfonic acid) diammonium salt (ABTS) and hydrogen peroxide, and then reacted with a microplate reader.
  • ABTS 2,2,1-azinobis (3-ethylbenzothiazoline 6-sulfonic acid) diammonium salt
  • the absorbance at 405 nm was measured. Furthermore, the amount of protein in each well was measured using the BCA Protein Assay Kit manufactured by PIERCE, and the amount of collagen produced per unit protein was determined.
  • the evaluation results are shown in Table 2 as relative values when the amount of collagen production per unit tank amount of the negative control is 100. In the table, ** indicates a significance probability of less than 1% (P ⁇ 0.01) with respect to significance P value in t-test.
  • B16 mouse melanoma (B16F0) cells were seeded at a density of 2000 cells per dish in a 35 mm dish.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS).
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the medium was changed to a medium adjusted to each concentration with 5% by mass FBS-added DMEM medium, and further cultured for 7 days. At this time, the sample is 5 masses with no additive.
  • / oFBS-added DMEM medium is a negative control (blank) and contains 5 mass of sodium lactate at a concentration of 50 mM.
  • / oFBS supplemented DMEM medium was used as a positive control.
  • the cells were collected using 0.25% trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate.
  • the resulting precipitate was visually judged based on Table 4 with respect to its blackish state.
  • negative control was evaluated as 5 and positive control was evaluated as 1, which was used as an index for determining the sample-added medium.
  • the tissue solubilizer (trade name: Solvable) was added to the precipitate and boiled, then cooled to room temperature, and the absorbance at 500 nm was measured. Table 5 shows the determination results and the absorbance at 500 nm.
  • a formulation example of a skin external preparation skin external preparation applicable as a moisturizing agent, a cell activator, a whitening agent, an antioxidant, etc.
  • the amount of each component means mass%.
  • the oil phase components (1) to (6) are heated and dissolved at 80 ° C.
  • the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C.
  • the oil phase component is added to this while stirring and emulsified uniformly with a homogenizer. After emulsification, start cooling and add (11) and (12) in order and mix uniformly.
  • Production method Dissolve (2) and (3) in (1). After dissolution, add (4) to (8) sequentially, and then stir well. Add (9) and mix uniformly.
  • the oil phase components (1) to (6) are heated and dissolved at 80 ° C.
  • the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C.
  • the oil phase component is added to this while stirring and emulsified uniformly with a homogenizer. After emulsification, add (11), start cooling, add (12) at 40 ° C and mix uniformly.
  • Production method Mix the aqueous phase components (1) to (6) and dissolve at 75 ° C.
  • the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C.
  • the mixture is uniformly emulsified with a homomixer. Start cooling after emulsification and cover (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
  • Manufacturing method Add (1) to (2), stir uniformly, and then add (3). After stirring uniformly, add (5) previously dissolved in (4). After stirring uniformly, add (6) to (8) previously mixed and stir and mix uniformly.
  • Manufacturing method Dissolve (1) and (2) uniformly. Add (3) and (4) to this, and mix evenly.
  • Production method The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and mixed with the oil phase components uniformly. Start cooling, add (8) at 40 ° C, and mix uniformly.
  • the oil phase components (1) to (4) are mixed and dissolved by heating at 75 ° C.
  • the aqueous phase components (5) to (7) are mixed, dissolved by heating at 75 ° C, and the pigments (8) to (10) are added thereto and dispersed uniformly with a homomixer.
  • the oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C, and mix evenly.
  • the oil phase components (1) to (6) are mixed and dissolved by heating at 75 ° C.
  • (7)-(10) The aqueous phase components are mixed and dissolved by heating at 75 ° C, and the pigments (11) to (15) are added thereto and dispersed uniformly with a homomixer.
  • Manufacturing method Dissolve (5) and (6) in a part of (11) to 50 ° C, and gradually add to (4) heated to 50 ° C while stirring. After mixing this, disperse uniformly in (1) to (3), which is heated and dissolved at 70 ° C. To this, heat (7) to (10) in the remainder of (11) and dissolve at 70 ° C while stirring and emulsify with a homomixer. Start cooling after emulsification, add (12) at 40 ° C, and mix uniformly.
  • Manufacturing method (2) and (3) are mixed, heated to 80 ° C, and then dissolved in (1) heated to 80 ° C. After evenly dissolving, add (4) and (5) and start cooling with stirring. Cool to 40 ° C, add (6) and (7), and mix evenly.
  • Production method (1) to (4) are mixed uniformly.
  • the oil phase components (1) to (6) are mixed and heated and dissolved at 75 ° C.
  • the aqueous phase components (7) to (10) are heated and dissolved at 75 ° C., and the oil phase components are collected and emulsified with a homomixer. Cooling is started after emulsification, and the ingredients (11) and (12) are collected at 40 ° C and evenly mixed. Mix.
  • Production method Components (1) to (4) are mixed and homogenized.
  • Production method (1) to (5) are mixed uniformly.
  • a use test was conducted using a prescription containing Nemagaridake extract, and the effect of improving skin roughness due to drying was evaluated.
  • the nematode mushroom extract shown in Table 6 was blended in the emulsion formulation shown in Formulation Example 1, and the use test was conducted as Examples 5 and 6.
  • the nematode mushroom extract was replaced with purified water, and a use test was conducted simultaneously as Comparative Example 1.
  • a composition containing negaridae can be applied as a moisturizer, cell activator, whitening agent or antioxidant.
  • the This composition can be used as a moisturizer, cell activator, whitening agent or antioxidant having an excellent effect.
  • Negararidake to a composition such as an external preparation for skin and foods and drinks, it is possible to obtain an excellent effect in preventing and improving skin symptoms such as wrinkles, tarmi, skin firmness, spots, and kusumi.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne une composition contenant du nemagaritake (Sasa kurilensis (Rupr) Makino) comme principe actif et dotée d'un effet hydratant, de stimulation des cellules, d'éclaircissement de la peau ou anti-oxydant. Par son addition à des compositions telles qu'une préparation pour usage cutané externe, à un aliment ou à une boisson, il est possible d'obtenir diverses compositions présentant d'excellents effets pour prévenir ou améliorer certains états de la peau tels que les rides, la santé de la peau, les taches, l'éclat, etc.
PCT/JP2006/315612 2006-08-07 2006-08-07 Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant Ceased WO2008018118A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2008528670A JP5014343B2 (ja) 2006-08-07 2006-08-07 ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤
PCT/JP2006/315612 WO2008018118A1 (fr) 2006-08-07 2006-08-07 Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2006/315612 WO2008018118A1 (fr) 2006-08-07 2006-08-07 Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant

Publications (1)

Publication Number Publication Date
WO2008018118A1 true WO2008018118A1 (fr) 2008-02-14

Family

ID=39032663

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/315612 Ceased WO2008018118A1 (fr) 2006-08-07 2006-08-07 Composition contenant du nemagaritake et un agent hydratant, un stimulant cellulaire, un agent de blanchiment et un anti-oxydant

Country Status (2)

Country Link
JP (1) JP5014343B2 (fr)
WO (1) WO2008018118A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010018530A (ja) * 2008-07-09 2010-01-28 Nihon Haruma Kk リンゴ二次残渣物又はチシマザサを原料とするチロシナーゼ阻害活性剤の抽出方法及びそのチロシナーゼ阻害活性剤
JP2015113291A (ja) * 2013-12-10 2015-06-22 共栄化学工業株式会社 皮膚化粧料
JP2019038766A (ja) * 2017-08-24 2019-03-14 佐藤　隆 皮脂産生促進剤
WO2022185819A1 (fr) * 2021-03-02 2022-09-09 ライオン株式会社 Composition d'agent de nettoyage de la peau

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5888303A (ja) * 1981-11-19 1983-05-26 Shiseido Co Ltd 化粧料
JPH09249550A (ja) * 1996-03-18 1997-09-22 Shiseido Co Ltd 皮膚外用剤
JP2000247864A (ja) * 1999-03-01 2000-09-12 Rasheru Seiyaku Kk 化粧料組成物
JP2002128632A (ja) * 2000-10-26 2002-05-09 Kyoei Kagaku Kogyo Kk 化粧料
JP2003231613A (ja) * 2002-02-06 2003-08-19 Kameda Seika Co Ltd 美白化粧料
JP2004161621A (ja) * 2002-11-11 2004-06-10 Pola Chem Ind Inc 角化酵素阻害剤及びそれを含有してなる皮膚外用剤
JP2004196731A (ja) * 2002-12-20 2004-07-15 Pola Chem Ind Inc 除毛用の化粧料
JP2004224750A (ja) * 2003-01-24 2004-08-12 Haba Laboratories Inc 美容液
JP2004269489A (ja) * 2002-05-28 2004-09-30 Haba Laboratories Inc 化粧料及びその製造方法
JP2004359698A (ja) * 2002-05-28 2004-12-24 Haba Laboratories Inc 化粧料の製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001261570A (ja) * 2000-03-22 2001-09-26 Nisshin Oil Mills Ltd:The 皮膚外用剤
CA2404012A1 (fr) * 2000-03-31 2001-10-04 The Nisshin Oil Mills, Ltd. Agent externe pour la peau et agent d'embellissement
JP2002212052A (ja) * 2001-01-15 2002-07-31 Hajime Ito 外用組成物
JP2002226386A (ja) * 2001-01-30 2002-08-14 Rohto Pharmaceut Co Ltd 植物抽出物を含有する外皮用組成物
JP2004284988A (ja) * 2003-03-24 2004-10-14 Kose Corp 毛髪化粧料及び毛髪の蛋白質のカルボニル化を抑制する方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5888303A (ja) * 1981-11-19 1983-05-26 Shiseido Co Ltd 化粧料
JPH09249550A (ja) * 1996-03-18 1997-09-22 Shiseido Co Ltd 皮膚外用剤
JP2000247864A (ja) * 1999-03-01 2000-09-12 Rasheru Seiyaku Kk 化粧料組成物
JP2002128632A (ja) * 2000-10-26 2002-05-09 Kyoei Kagaku Kogyo Kk 化粧料
JP2003231613A (ja) * 2002-02-06 2003-08-19 Kameda Seika Co Ltd 美白化粧料
JP2004269489A (ja) * 2002-05-28 2004-09-30 Haba Laboratories Inc 化粧料及びその製造方法
JP2004359698A (ja) * 2002-05-28 2004-12-24 Haba Laboratories Inc 化粧料の製造方法
JP2004161621A (ja) * 2002-11-11 2004-06-10 Pola Chem Ind Inc 角化酵素阻害剤及びそれを含有してなる皮膚外用剤
JP2004196731A (ja) * 2002-12-20 2004-07-15 Pola Chem Ind Inc 除毛用の化粧料
JP2004224750A (ja) * 2003-01-24 2004-08-12 Haba Laboratories Inc 美容液

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010018530A (ja) * 2008-07-09 2010-01-28 Nihon Haruma Kk リンゴ二次残渣物又はチシマザサを原料とするチロシナーゼ阻害活性剤の抽出方法及びそのチロシナーゼ阻害活性剤
JP2015113291A (ja) * 2013-12-10 2015-06-22 共栄化学工業株式会社 皮膚化粧料
JP2019038766A (ja) * 2017-08-24 2019-03-14 佐藤　隆 皮脂産生促進剤
JP7041913B2 (ja) 2017-08-24 2022-03-25 隆 佐藤 皮脂産生促進剤
WO2022185819A1 (fr) * 2021-03-02 2022-09-09 ライオン株式会社 Composition d'agent de nettoyage de la peau
JP2022133728A (ja) * 2021-03-02 2022-09-14 ライオン株式会社 皮膚洗浄剤組成物
JP7736408B2 (ja) 2021-03-02 2025-09-09 ライオン株式会社 液体皮膚洗浄剤組成物

Also Published As

Publication number Publication date
JPWO2008018118A1 (ja) 2009-12-24
JP5014343B2 (ja) 2012-08-29

Similar Documents

Publication Publication Date Title
WO2008029798A1 (fr) Activateur cellulaire, promoteur de la production de collagène, agent blanchissant la peau, agent anti-oxydant, agent anti-inflammatoire, promoteur de l'activité aromatase, promoteur de l'activité protéase, préparation externe pour la peau et aliment
JP4921754B2 (ja) メラニン産生促進剤及び中性脂肪蓄積抑制剤
JP5014343B2 (ja) ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤
JP5465037B2 (ja) 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物
JP5557414B2 (ja) 保湿剤、細胞賦活剤、及び美白剤
JP4201091B1 (ja) 保湿剤、抗老化剤、抗酸化剤及び皮膚外用剤
JP5062980B2 (ja) 保湿剤、コラーゲン産生促進剤、美白剤、抗酸化剤、及び血管内皮細胞増殖因子産生促進剤
JP4748962B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4334956B2 (ja) 細胞賦活剤、美白剤、及び抗酸化剤
JP2011246375A (ja) 美白剤、抗酸化剤、皮膚外用剤、及び機能性経口組成物
JP5550929B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、皮膚外用剤及び機能性経口組成物
JP4050727B2 (ja) 保湿剤、細胞賦活剤、美白剤、抗酸化剤、及び皮膚外用剤
JP4480366B2 (ja) 細胞賦活剤、美白剤、ヒアルロン酸産生促進剤、コラーゲン産生促進剤、抗酸化剤、及び皮膚外用剤
JP4994684B2 (ja) 保湿剤、細胞賦活剤、及び抗酸化剤
WO2008035572A1 (fr) Agent hydratant, agent anti-vieillissement, agent blanchissant la peau et agent anti-oxydant
JP4970442B2 (ja) 美白剤
JP4291647B2 (ja) 細胞賦活剤、美白剤、コラーゲン産生促進剤、抗酸化剤、及び皮膚外用剤
JP4931452B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4869638B2 (ja) 細胞賦活剤、美白剤、抗酸化剤、アミラーゼ阻害剤、及び保湿剤
JP5202180B2 (ja) 保湿剤、免疫賦活剤、抗老化剤、美白剤、抗酸化剤、痩身剤、皮膚外用剤及び機能性経口組成物
JP4916150B2 (ja) 保湿剤、細胞賦活剤、抗酸化剤、及び皮膚外用剤、
JP5383384B2 (ja) 抗老化剤、抗酸化剤、美白剤、及び免疫賦活剤
JP2011225477A (ja) 抗老化剤、抗酸化剤、皮膚外用剤および機能性経口組成物
JP2013147438A (ja) ｃＡＭＰ産生抑制剤
JP2011168559A (ja) 抗酸化剤、抗炎症剤、抗老化剤、皮膚外用剤、及び機能性経口組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06782454

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008528670

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06782454

Country of ref document: EP

Kind code of ref document: A1